Celestial Therapeutics Inc.
Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.
Industries
Nr. of Employees
small (1-50)
Celestial Therapeutics Inc.
3210 Merryfield Row San Diego, CA 92121
Celestial Therapeutics Inc. is currently seeking investment
Celestial Therapeutics Inc. is seeking a seed investment in the range of 5m-20m
Products
Inhaled pulmonary surfactant lipid-derived dual-modal antiviral/anti-inflammatory therapeutic (lead candidate)
A pulmonary surfactant-derived phospholipid therapeutic candidate developed as a dual-modal antiviral and anti-inflammatory inhalation product intended to treat respiratory viral infections. Development includes dry powder inhalation formulation work for ambient-stable delivery.
Self-adjuvanting mRNA vaccine platform and prototype mRNA vaccine candidates
A licensed mRNA platform that encodes antigen and immunostimulatory RNA within a single mRNA construct to elicit tunable innate and adaptive immune responses; includes prototype vaccine development (example: candidate against Chikungunya supported by preclinical funding).
Inhaled pulmonary surfactant lipid-derived dual-modal antiviral/anti-inflammatory therapeutic (lead candidate)
A pulmonary surfactant-derived phospholipid therapeutic candidate developed as a dual-modal antiviral and anti-inflammatory inhalation product intended to treat respiratory viral infections. Development includes dry powder inhalation formulation work for ambient-stable delivery.
Self-adjuvanting mRNA vaccine platform and prototype mRNA vaccine candidates
A licensed mRNA platform that encodes antigen and immunostimulatory RNA within a single mRNA construct to elicit tunable innate and adaptive immune responses; includes prototype vaccine development (example: candidate against Chikungunya supported by preclinical funding).
Expertise Areas
- mRNA vaccine development
- Inhaled antiviral/anti-inflammatory therapeutics
- Pulmonary surfactant lipid chemistry
- Preclinical development and translational research
Key Technologies
- Self-adjuvanting mRNA constructs (antigen + immunostimulatory RNA in single transcript)
- Immunostimulatory RNA targeting RIG-I pathway
- Pulmonary surfactant-derived lipid therapeutics
- Dry powder inhalation formulation
Key People
Ajay Gupta, Ph.D.
Co-founder, President, Chairman & CEO
Leontis Teryazos, B.A.
Co-founder, Chief Financial Officer, Corporate Secretary & Board Member
George Siber, M.D.
Board Member
George Church, Ph.D.
Scientific Advisor
Sir Michael Houghton, Ph.D., D.Sc. Hon., Nobel Laureate
Scientific Advisor
Ajay Gupta, Ph.D.
Co-founder, President, Chairman & CEO
Leontis Teryazos, B.A.
Co-founder, Chief Financial Officer, Corporate Secretary & Board Member
George Siber, M.D.
Board Member
George Church, Ph.D.
Scientific Advisor
Sir Michael Houghton, Ph.D., D.Sc. Hon., Nobel Laureate
Scientific Advisor
News & Updates
Dr. George Church, a Professor at Harvard and MIT, has joined Celestial’s Scientific Advisory Board, bringing expertise in genetics and synthetic biology.
Dr. Michael Houghton, a Nobel Prize winner in Physiology or Medicine, has joined Celestial’s Scientific Advisory Board, contributing his expertise in virology and immunology.
Celestial Therapeutics has been accepted into Johnson & Johnson Innovation – JLABS as a resident company at its flagship site in San Diego, California.
Celestial Therapeutics has been accepted into the Mayo Clinic Innovation Exchange to advance its lead dual modal antiviral/anti-inflammatory therapeutic, CT-02, for the treatment of viral myocarditis into human clinical trials.
Celestial Therapeutics has been selected to join the Endless Frontier Labs 2021-2022 cohort alongside 75 ground-breaking companies.
Celestial Therapeutics has been accepted into the StartX community for the Summer 2021 cohort, a prominent technology accelerator in Silicon Valley.
Dr. George Church, a Professor at Harvard and MIT, has joined Celestial’s Scientific Advisory Board, bringing expertise in genetics and synthetic biology.
Dr. Michael Houghton, a Nobel Prize winner in Physiology or Medicine, has joined Celestial’s Scientific Advisory Board, contributing his expertise in virology and immunology.
Celestial Therapeutics has been accepted into Johnson & Johnson Innovation – JLABS as a resident company at its flagship site in San Diego, California.
Celestial Therapeutics has been accepted into the Mayo Clinic Innovation Exchange to advance its lead dual modal antiviral/anti-inflammatory therapeutic, CT-02, for the treatment of viral myocarditis into human clinical trials.
Celestial Therapeutics has been selected to join the Endless Frontier Labs 2021-2022 cohort alongside 75 ground-breaking companies.
Celestial Therapeutics has been accepted into the StartX community for the Summer 2021 cohort, a prominent technology accelerator in Silicon Valley.